A top vaccines official at the World Health Organization (WHO) told that the agency expects to make a decision next month on an emergency authorisation for the coronavirus vaccine, Covaxin, made by Hyderabad-based Bharat Biotech, a shot that has yet to be approved by any Western regulatory authority.
The UN health agency’s review of the Bharat Biotech vaccine was “quite advanced,” according to Dr Mariangela Simao, a WHO assistant director-general for Covid-19 vaccines, and authorities anticipated for a decision by mid-September, according to the report.
Only a few studies on the shot have been published. Indian researchers have yet to publish any advanced studies on the coronavirus vaccine, which has been approved for use in the country.
Covaxin 78% effective
The Covid vaccine, according to Indian scientists, is roughly 78 percent effective, but there are some concerns about how it operates in the real world, notably against coronavirus variants.
WHO is also evaluating other versions of vaccines that have already been approved by the agency, including one developed by Sinopharm, according to Simao. In September, she expects them to start studying vaccines made by Sanofi Pasteur and Novavax.
Novavax’s producers in the United States recently stated that they would seek approval in underdeveloped nations and from the World Health Organization (WHO) before seeking approval in the United States and the European Union.
“There are many, many vaccines in the final stages of the pipeline,” Simao says.
Meanwhile, the WHO said that three anti-inflammatory medications would be studied in a clinical trial involving 52 countries as prospective treatments for Covid-19 patients.
“These therapies – artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients,” it said in a statement on the Solidarity PLUS trial.
Thousands of researchers from over 600 hospitals are involved in the trial, according to WHO Director-General Tedros Adhanom Ghebreyesus, who spoke at a news conference in Geneva.